1. In Vivo
  2. >>Business Strategy

Pfizer/Angiosyn: Building Biotechs for Device-style Early M&A

Pfizer's acquisition of privately-held Angiosyn is basically a milestones-and-royalty-based licensing deal for the biotech's preclinical non-VEGF targeting AMD candidate. Angiosyn was designed for early M&A, much like most medical device firms of the past ten years, and this risk-sharing agreement with Pfizer may imply a new, leaner model for biotech company building.

While the press surrounding Pfizer Inc. 's acquisition of privately held Angiosyn Inc. in mid-January suggested a $527 million blockbuster deal for the tiny California biotech, the immediate financial reality behind the biobucks headlines was slightly more mundane [See Deal].

Angiosyn was formed in May 2003 by the Scripps Research Institute's Paul Schimmel, PhD, with backing from venture firm Alta...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business Strategy

More from In Vivo

EU Medtech Outlook: The View From MedTech Europe Experts

 
• By Ashley Yeo

MedTech Forum 2025 was less MDR-focused than in previous years, as macro issues and exogenous threats were forced further into the center of medtech business thinking.

‘Confident In Lorundrostat’s Promise’: Mineralys CEO Talks Trials And Next Steps

 
• By Sushmita Panda

In a conversation with In Vivo, CEO Jon Congleton discusses Mineralys’s data-rich journey toward an NDA filing, the significance of recent trial wins and how its candidate may offer a dual benefit in blood pressure and renal protection.

BioBytes: Qubit Pharmaceuticals Unveils Quantum AI Model For Drug Discovery

 
• By David Wild

Qubit Pharmaceuticals and Sorbonne University launched a quantum AI model that could slash drug synthesis requirements and enable exploration of previously undruggable targets.